NIKKEI 225
30,500.05+176.75(+0.58%)HANG SENG
23,960.27-960.49(-3.85%)CRUDE OIL
71.37-0.60(-0.83%)GOLD FUTURES
1,748.70-2.70(-0.15%)DOW
34,584.88-166.42(-0.48%)BTC-GBP
33,309.15-1,759.54(-5.02%)
Fresenius SE & Co. KGaA (FRE.DE)
| Previous close | 40.83 |
| Open | 41.03 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 40.81 - 41.34 |
| 52-week range | 31.03 - 47.60 |
| Volume | 2,642,741 |
| Avg. volume | 943,813 |
| Market cap | 27.11B |
| Beta (5Y monthly) | 1.26 |
| PE ratio (TTM) | 13.55 |
| EPS (TTM) | 3.02 |
| Earnings date | 02 Nov 2021 |
| Forward dividend & yield | 0.88 (2.00%) |
| Ex-dividend date | 25 May 2021 |
| 1y target est | N/A |
- Motley Fool
Is Cara Therapeutics Stock a Buy After Its First FDA Drug Approval
Cara Therapeutics (NASDAQ: CARA) recently scored a key win with Food and Drug Administration approval of Korsuva in treating pruritis associated with chronic kidney disease for patients on hemodialysis. In this Motley Fool Live video recorded on Aug. 25, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not Cara stock is a buy after the big news. Another biotech had some good news on the FDA front: Cara Therapeutics, ticker there is CARA, and its partner Vifor Pharma (OTC: GNHAY) announced on Monday that the FDA had approved Korsuva for trading moderate to severe pruritus associated with chronic kidney disease, and this is in adults undergoing dialysis.
- Reuters
Healthcare group Fresenius raises 2021 forecasts
German healthcare group Fresenius raised 2021 targets though it saw a weaker third quarter, saying progress on its cost-cutting plan should offset troubles at its dialysis unit. The COVID-19 pandemic has affected healthcare groups in different ways as demand for coronavirus-related products and services coincided with the evolution of new coronavirus variants and higher rates of patient deaths. Fresenius said that while it earlier expected lower pandemic effects in late 2021, new coronavirus variants and exposure to high-risk patients at its dialysis unit Fresenius Medical Care could threaten those assumptions in the third quarter.
- Zacks
Is FRESENIUS SE&CO (FSNUY) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
